ProCE Banner Activity

CheckMate 9ER: Efficacy of First-line Nivolumab + Cabozantinib vs Sunitinib in Advanced/Metastatic RCC by Baseline Patient Characteristics

Slideset Download
Conference Coverage

Exploratory analyses of the CheckMate 9ER trial suggested PFS benefit with nivolumab + cabozantinib vs sunitinib across assessed subgroups defined by baseline disease characteristics.

Released: June 06, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme